Stock listing
BOATS:AVBP ArriVent BioPharma, Inc. Stock
US listing (BOATS) of ArriVent BioPharma, Inc. · home listing NASDAQ:AVBP
Follow ArriVent BioPharma, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:AVBP
$13.49 USD +0.47 (+3.6%)
Close on Nov 4, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:AVBP
- Day range
- $12.47 – $13.57 USDNov 4, 2026
- Volume
- 1.62M sharesNov 4, 2026
- Market cap
- $665.2M USDAt the close on Nov 4, 2026 · price × 49.31M shares outstanding
- 52-week range
- $11.36 – $35.83 USDLowest and highest trades, Nov 5, 2025 – Nov 4, 2026
- Traded on an average day
- $24.31M USDMedian day 600,400 shares · last 3 months, Aug 4, 2026 – Nov 4, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:AVBP · Home | $13.49 USD | +0.47 (+3.6%) | 1,624,627 | $13.39 | $13.57 | $12.47 | $13.02 | Close on Nov 4, 2026 |
Daily closes
Last 3 months, Aug 4, 2026 – Nov 4, 2026 · NASDAQ:AVBP · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $13.49 | +0.47 | +3.6% | $13.39 | $13.57 | $12.47 | 1,624,627 | |
| $13.02 | -0.33 | -2.5% | $13.47 | $13.94 | $13.01 | 1,226,259 | |
| $13.35 | -1.52 | -10.2% | $14.89 | $14.98 | $13.26 | 1,237,292 | |
| $14.87 | -1.08 | -6.8% | $15.78 | $16.17 | $14.33 | 1,194,900 | |
| $15.95 | +0.22 | +1.4% | $15.87 | $16.42 | $15.73 | 658,000 | |
| $15.73 | +0.33 | +2.1% | $15.67 | $15.89 | $15.20 | 990,000 | |
| $15.40 | +0.04 | +0.3% | $15.45 | $15.69 | $15.00 | 1,582,000 | |
| $15.36 | -5.64 | -26.9% | $18.14 | $18.16 | $14.78 | 5,946,900 | |
| $21.00 | +1.80 | +9.4% | $19.00 | $21.23 | $18.18 | 3,277,900 | |
| $19.20 | +0.08 | +0.4% | $18.93 | $19.68 | $18.78 | 843,700 | |
| $19.12 | +0.27 | +1.4% | $19.07 | $19.44 | $18.68 | 1,489,200 | |
| $18.85 | +0.91 | +5.1% | $17.94 | $18.98 | $17.57 | 817,800 | |
| $17.94 | +1.28 | +7.7% | $16.82 | $18.14 | $16.73 | 1,013,200 | |
| $16.66 | -0.13 | -0.8% | $16.86 | $17.23 | $16.49 | 1,334,000 | |
| $16.79 | +0.59 | +3.6% | $16.40 | $16.91 | $15.97 | 814,900 | |
| $16.20 | +0.11 | +0.7% | $16.06 | $16.62 | $15.26 | 1,589,100 | |
| $16.09 | -0.37 | -2.2% | $16.28 | $16.72 | $15.95 | 1,968,300 | |
| $16.46 | -0.27 | -1.6% | $16.57 | $16.78 | $16.26 | 1,335,400 | |
| $16.73 | +0.02 | +0.1% | $16.59 | $17.76 | $16.49 | 1,731,100 | |
| $16.71 | -0.18 | -1.1% | $16.62 | $16.91 | $15.78 | 2,154,200 | |
| $16.89 | +1.80 | +11.9% | $15.25 | $17.35 | $14.97 | 4,332,600 | |
| $15.09 | -13.37 | -47.0% | $12.09 | $15.79 | $11.36 | 19,742,400 | |
| $28.46 | +0.19 | +0.7% | $28.00 | $28.70 | $27.02 | 494,800 | |
| $28.27 | -0.66 | -2.3% | $29.26 | $29.33 | $27.80 | 507,600 | |
| $28.93 | -1.35 | -4.5% | $29.99 | $30.64 | $28.81 | 591,800 | |
| $30.28 | +0.74 | +2.5% | $29.69 | $30.90 | $29.65 | 712,500 | |
| $29.54 | +0.24 | +0.8% | $29.30 | $30.05 | $28.80 | 780,000 | |
| $29.30 | +0.85 | +3.0% | $28.38 | $29.90 | $28.02 | 1,016,600 | |
| $28.45 | -1.65 | -5.5% | $30.16 | $30.55 | $28.43 | 653,200 | |
| $30.10 | -0.20 | -0.7% | $29.94 | $30.51 | $29.24 | 609,000 | |
| $30.30 | -0.02 | -0.1% | $30.32 | $31.49 | $29.84 | 1,206,000 | |
| $30.32 | +0.58 | +2.0% | $30.22 | $30.50 | $29.56 | 389,100 | |
| $29.74 | +0.84 | +2.9% | $29.17 | $31.16 | $28.20 | 937,000 | |
| $28.90 | +0.54 | +1.9% | $29.00 | $29.64 | $28.62 | 1,238,500 | |
| $28.36 | +0.71 | +2.6% | $28.24 | $28.45 | $27.84 | 456,400 | |
| $27.65 | -0.32 | -1.1% | $28.15 | $28.31 | $27.28 | 379,400 | |
| $27.97 | -0.60 | -2.1% | $28.51 | $28.75 | $27.70 | 337,300 | |
| $28.57 | -0.43 | -1.5% | $29.10 | $29.83 | $28.40 | 538,300 | |
| $29.00 | +0.30 | +1.0% | $29.16 | $29.21 | $28.15 | 1,132,000 | |
| $28.70 | -1.09 | -3.7% | $29.33 | $30.53 | $28.54 | 564,200 | |
| $29.79 | -0.49 | -1.6% | $30.02 | $30.26 | $29.40 | 280,100 | |
| $30.28 | -0.67 | -2.2% | $30.57 | $31.40 | $30.02 | 722,000 | |
| $30.95 | -0.08 | -0.3% | $30.79 | $31.45 | $30.60 | 182,400 | |
| $31.03 | +0.52 | +1.7% | $30.58 | $31.39 | $30.22 | 465,400 | |
| $30.51 | +0.36 | +1.2% | $30.33 | $30.79 | $29.60 | 423,900 | |
| $30.15 | +0.10 | +0.3% | $30.10 | $30.33 | $29.70 | 356,100 | |
| $30.05 | -0.12 | -0.4% | $29.94 | $30.26 | $29.35 | 369,600 | |
| $30.17 | -0.83 | -2.7% | $30.53 | $31.37 | $29.75 | 353,500 | |
| $31.00 | -0.14 | -0.4% | $30.79 | $31.77 | $30.24 | 300,000 | |
| $31.14 | -0.21 | -0.7% | $31.21 | $31.41 | $30.11 | 433,800 | |
| $31.35 | +3.09 | +10.9% | $28.64 | $31.52 | $28.64 | 961,653 | |
| $28.26 | -0.86 | -3.0% | $29.02 | $29.02 | $28.05 | 225,594 | |
| $29.12 | -0.06 | -0.2% | $29.45 | $29.77 | $28.95 | 304,800 | |
| $29.18 | -0.84 | -2.8% | $29.73 | $29.81 | $28.64 | 406,300 | |
| $30.02 | +0.02 | +0.1% | $30.13 | $30.45 | $29.31 | 522,800 | |
| $30.00 | +0.99 | +3.4% | $28.86 | $30.37 | $28.86 | 408,700 | |
| $29.01 | -0.50 | -1.7% | $29.30 | $29.63 | $28.57 | 455,200 | |
| $29.51 | -0.49 | -1.6% | $29.99 | $30.07 | $29.13 | 439,000 | |
| $30.00 | -1.46 | -4.6% | $30.73 | $30.96 | $29.40 | 478,900 | |
| $31.46 | +0.07 | +0.2% | $31.18 | $31.60 | $30.86 | 295,800 | |
| $31.39 | +0.40 | +1.3% | $31.13 | $31.60 | $30.57 | 453,365 | |
| $30.99 | +0.15 | +0.5% | $30.79 | $31.28 | $30.25 | 471,947 | |
| $30.84 | -0.17 | -0.5% | $31.57 | $31.79 | $30.27 | 302,100 | |
| $31.01 | +0.40 | +1.3% | $30.61 | $31.51 | $30.08 | 181,600 | |
| $30.61 | -0.88 | -2.8% | $31.59 | $31.83 | $30.05 | 500,400 | |
| $31.49 | +1.85 | +6.2% | $30.04 | $31.89 | $29.80 | 427,500 |
- Ticker
- BOATS:AVBP
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Oct 25, 2026
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 21 slides
Latest news
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
Oct 25, 2026
Closed $15.36 (-26.9%) on Oct 26, 2026
ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer
Oct 19, 2026
Closed $17.94 (+7.7%) on Oct 19, 2026
ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002
Oct 12, 2026
Closed $16.09 (-2.2%) on Oct 13, 2026
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
Oct 6, 2026
Closed $15.09 (-47.0%) on Oct 6, 2026
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
Aug 12, 2026
Closed $30.00 (-4.6%) on Aug 13, 2026
ArriVent BioPharma Reports First Quarter 2026 Financial Results
May 11, 2026
Closed $29.02 (-1.6%) on May 11, 2026
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
May 7, 2026
Closed $28.85 (-2.6%) on May 7, 2026
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
Mar 17, 2026
Closed $22.81 (-5.0%) on Mar 18, 2026
ArriVent BioPharma Reports Full Year 2025 Financial Results
Mar 5, 2026
Closed $25.25 (-4.9%) on Mar 5, 2026
Decks
Investor Presentation (August 2026)
Investor deck · 21 slides · August 2026
Investor Presentation (June 2025)
Investor deck · 25 slides · Jun 23, 2025
Technical Presentation (September 2024)
Technical · 13 slides · Sep 8, 2024
European Lung Cancer Congress 2022
Conference · 12 slides · Mar 18, 2022
ArriVent BioPharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 12 in the last 12 months · 33 in all · newest Oct 25, 2026 · oldest 2024
- Decks
- 4 decks · latest August 2026
Where ArriVent BioPharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:AVBP · Home listing | NASDAQ | United States | USD |
| BOATS:AVBP · This page | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about ArriVent BioPharma, Inc.